Oncopeptides AB (publ) (FRA:OND)

Market Cap	144.36M
Revenue (ttm)	5.65M
Net Income (ttm)	-24.23M
Shares Out	n/a
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	1,082
Open	0.4755
Previous Close	0.4560
Day's Range	0.4755 - 0.5000
52-Week Range	0.1108 - 0.5960
Beta	n/a
RSI	59.77
Earnings Date	Feb 27, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 80
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: OND

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.

Financial numbers in SEK